Windlas Biotech Ltd

Fri 4/09/2026,15:59:2 | NSE : WINDLAS

₹1126.35-0.75 (-0.07%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1129.90

Previous Close

₹ 1127.10

Volume

190854

Mkt Cap ( ₹ Cr)

₹ 2364.02

High

₹ 1152.40

Low

₹ 1115.00

52 Week High

₹ 1152.40

52 Week Low

₹ 697.40

Book Value Per Share

₹ 276.72

Dividend Yield

0.00

Face Value

₹ 5.00

What's Your Call?

Collective community sentiment on Windlas Biotech Ltd

Your Vote -

Buy

21.74%

Hold

56.52%

Sell

21.74%

21.74%

46 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1126.35

63

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

63

Option Chain

Analyzes market sentiment, predicts Windlas Biotech Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Sep 2026, 5:47PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Sep 2026, 5:42PM Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Windlas Biotech Q1 net profit down 0.11% at Rs 17.65 cr

    25 Aug 2026, 10:00AM The company reported standalone net profit of Rs 17.65 crore for the quarter ended June 30, 2026 as compared to Rs 17.67 crore in the same period last
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Aug 2026, 3:05PM Windlas Biotech Limited has informed the Exchange about earnings call transcript of Q1 FY27
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    14 Aug 2026, 2:59PM Q1 FY27 Earnings Conference Call Transcript enclosed.
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Aug 2026, 2:07PM Windlas Biotech Limited has informed the Exchange about Link of Recording
  • Windlas Biotech - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2

    11 Aug 2026, 2:04PM Audio Recording Q1 conference call
  • Windlas Biotech - Press Release

    10 Aug 2026, 4:09PM Windlas Biotech Limited has informed the Exchange regarding a press release dated August 10, 2026, titled ""press release on ""Windlas Biotech Limited
  • Windlas Biotech - Investor Presentation

    10 Aug 2026, 4:05PM Windlas Biotech Limited has informed the Exchange about Investor Presentation
  • Windlas Biotech - Outcome of Board Meeting

    10 Aug 2026, 3:38PM Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    10 Aug 2026, 4:16PM Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Investor Presentation

    10 Aug 2026, 4:13PM Investor Presentation - Q1 FY27 enclosed
  • Windlas Biotech - Outcome Of The Board Meeting Held On August 10, 2026

    10 Aug 2026, 3:30PM approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
  • Windlas Biotech - Board Meeting Outcome for Outcome Of The Board Meeting Held On August 10, 2026

    10 Aug 2026, 3:23PM approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Aug 2026, 3:07PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Aug 2026, 1:54PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Aug 2026, 3:03PM Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Aug 2026, 1:45PM Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026
  • Windlas Biotech - Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Monday, August 10, 2026

    4 Aug 2026, 4:41PM Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    24 Jul 2026, 5:29PM Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Re
  • Windlas Biotech - Shareholders meeting

    24 Jul 2026, 5:06PM Submission of Combined Voting Results and Scrutinizer s Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Re
  • Windlas Biotech - Shareholders meeting

    24 Jul 2026, 5:00PM Windlas Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 23, 2025. Further, the company ha
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    24 Jul 2026, 4:40PM Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Re
  • Windlas Biotech - Shareholders meeting

    23 Jul 2026, 3:08PM Windlas Biotech Limited has informed the Exchange about the proceedings of Annual General Meeting of the Company held on July 23, 2026.
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    24 Jul 2026, 5:29PM Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Re
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    24 Jul 2026, 4:40PM Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Re
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Outcome of AGM

    23 Jul 2026, 3:00PM Proceedings of 25th Annual General Meeting of the Company held on July 23, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclo
  • Windlas Biotech has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    16 Jul 2026, 6:10PM As of June 2026, 63.31% is owned by Indian Promoters and 36.69% by Public. <p align=justify> Top three Promoters holding highest number of shares of W
  • Windlas Biotech - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Jul 2026, 2:20PM Windlas Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Windlas Biotech - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Jul 2026, 1:54PM Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    9 Jul 2026, 7:32PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    9 Jul 2026, 7:27PM Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Windlas Biotech has declared 126% Final dividend for the financial year March 2026

    3 Jul 2026, 2:50PM Windlas Biotech Ltd. on Thursday, 21 May 2026, has announced Final dividend of 126 percent on Equity Share, to its shareholders holding shares on the
  • Windlas Biotech - General Updates

    2 Jul 2026, 3:40PM Windlas Biotech Limited has informed the Exchange about completion of despatch of Notice of 25th AGM and the Annual Report for FY26
  • Windlas Biotech - General Updates

    1 Jul 2026, 7:45PM Windlas Biotech Limited has informed the Exchange about record date/ cut-off date for the purpose of AGM
  • Windlas Biotech - Intimation Of Record Date/ Cut-Off Date For The 25Th AGM And Evoting

    1 Jul 2026, 7:40PM Intimation of record date/ cut-off date for the 25th AGM and evoting
  • Windlas Biotech - Reg. 34 (1) Annual Report.

    1 Jul 2026, 7:24PM Annual Report for FY26
  • Windlas Biotech - Shareholders meeting

    1 Jul 2026, 2:09PM Windlas Biotech Limited has informed the Exchange about the Annual General Meeting to be held on July 23, 2026
  • Windlas Biotech - Record Date

    1 Jul 2026, 12:44PM Windlas Biotech Limited has informed the Exchange that Record date for the purpose of Dividend is 16-Jul-2026.
  • Windlas Biotech - Notice Of 25Th AGM To Be Held On July 23, 2026

    1 Jul 2026, 2:13PM Notice of 25th AGM to be held on July 23, 2026
  • Windlas Biotech - Notice Of 25Th AGM

    1 Jul 2026, 1:55PM Notice of 25th AGM
  • Windlas Biotech - Intimation Of Cut-Off Date For Evoting And Dividend

    1 Jul 2026, 12:37PM Intimation of cut-off date for evoting and dividend
  • Windlas Biotech - Copy of Newspaper Publication

    30 Jun 2026, 1:58PM Windlas Biotech Limited has informed the Exchange about Copy of Newspaper Publication
  • Windlas Biotech - Credit Rating

    29 Jun 2026, 4:29PM Windlas Biotech Limited has informed the Exchange about Credit Rating
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Credit Rating

    29 Jun 2026, 4:25PM Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015- Credi
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Jun 2026, 2:56PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Jun 2026, 2:53PM Intimation of Schedule of Analyst/Institutional Investor Meetings
  • Windlas Biotech - Trading Window

    25 Jun 2026, 5:53PM Windlas Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Jun 2026, 1:15PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Jun 2026, 1:13PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Jun 2026, 12:55PM Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Jun 2026, 12:47PM Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Windlas Biotech

    2 Feb 2022 , 9:47AM Windlass Biotech: The company’s plant IV at Dehradhun underwent an inspection from the SAPHRA (South African Health Products Regulatory Authority) between 20-29th September 2021. The inspection ended with zero critical observations/ deficiencies, zero major deficiencies and some minor deficiencies. This is positive as a successful inspection would open up new geography and help it strengthen its presence in South Africa.

Key fundamentals

Evaluate the intrinsic value of Windlas Biotech Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 610.708 532.905 450.4 403.109 401.247
Liabilities 610.708 532.905 450.4 403.109 401.247
Equity 10.553 10.48 10.399 10.463 10.897
Gross Profit 104.695 94.115 78.102 60.242 52.895
Net Profit 66.435 60.649 58.144 42.644 38.561
Cash From Operating Activities 104.927 68.232 108.911 60.982 8.997
NPM(%) 7.34 7.98 9.21 8.31 8.27
Revenue 904.089 759.878 630.956 513.083 465.93
Expenses 799.394 665.763 552.854 452.841 413.035
ROE(%) 11.43 10.44 10.01 7.34 6.63

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
16 Jul 2026 6.3 126 0 782.35
21 Jul 2025 5.8 116 0 970.95
17 Sep 2024 5.5 110 0 607.95
09 Sep 2022 3.5 70 0 215.8

Peers

Other companies within the same industry or sector that are comparable to Windlas Biotech Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 860.25 -1.14 21.76 641.69 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.43 0.14 1563.29 2338.23 0.39 0.00
Vaishali Pharma Ltd 8.32 -0.48 26.00 14668.51 15.42 0.00
Astec Lifesciences Ltd 554.45 -3.28 0.00 2505.29 -363.14 0.00

Company Info

The Company was incorporated as `Windlas Biotech Limited' on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by RoC Delhi. Further, the Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by the Shareholders on August 22, 2009. The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand located at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by the Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand located at Kanpur on July 22, 2016. the Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by the Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021 consequent upon change of name on conversion to a public limited company was granted by the RoC.Major events and milestones of the Company :2001- Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production2009- Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 1102010- Revenues crossed Rs. 1,000 million for the FY 2009-102014- Received first USFDA inspection clearance for the WHC Plant- Revenues crossed Rs. 2,000 million for the FY 2013-14- Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 1102015- Investment of Rs. 750 million from Tano India Private Equity Fund II2017- Revenues crossed Rs. 3,000 million for the FY 2016-172018- Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110- Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun 248 1972021- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company 2022 -Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority).

The Company was incorporated as `Windlas Biotech Limited' on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by RoC Delhi. Further, the Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by the Shareholders on August 22, 2009. The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand located at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by the Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand located at Kanpur on July 22, 2016. the Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by the Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021 consequent upon change of name on conversion to a public limited company was granted by the RoC.Major events and milestones of the Company :2001- Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production2009- Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 1102010- Revenues crossed Rs. 1,000 million for the FY 2009-102014- Received first USFDA inspection clearance for the WHC Plant- Revenues crossed Rs. 2,000 million for the FY 2013-14- Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 1102015- Investment of Rs. 750 million from Tano India Private Equity Fund II2017- Revenues crossed Rs. 3,000 million for the FY 2016-172018- Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110- Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun 248 1972021- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company 2022 -Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority).

Parent Organisation

Windlas Biotech Ltd.

Founded

19/02/2001

Managing Director

Mr.Hitesh Windlass

NSE Symbol

WINDLASEQ

FAQ